KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Receivables - Net (2016 - 2025)

Pfizer (PFE) has disclosed Receivables - Net for 17 consecutive years, with $11.9 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 3.59% to $11.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.9 billion, a 3.59% increase, with the full-year FY2025 number at $11.9 billion, up 3.59% from a year prior.
  • Receivables - Net was $11.9 billion for Q4 2025 at Pfizer, down from $14.3 billion in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $16.1 billion in Q4 2022 to a low of $9.9 billion in Q2 2021.
  • A 5-year average of $12.1 billion and a median of $11.7 billion in 2023 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 45.07% in 2021, then plummeted 32.49% in 2023.
  • Pfizer's Receivables - Net stood at $11.5 billion in 2021, then decreased by 4.59% to $11.0 billion in 2022, then increased by 5.61% to $11.6 billion in 2023, then dropped by 0.89% to $11.5 billion in 2024, then increased by 3.59% to $11.9 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Receivables - Net are $11.9 billion (Q4 2025), $14.3 billion (Q3 2025), and $12.1 billion (Q2 2025).